GAST SIM-C-03/2019. FOCUS ON ULCERATIVE COLITIS Maximizing the outcome of UC therapy: the impact of a patient tailored approach

Transcript

1 GAST SIM-C-03/2019 FOCUS ON ULCERATIVE COLITIS Maximizing the outcome of UC therapy: the impact of a patient tailored approach Bologna e Roma MAGGIO 2017

2 Chairmen Roma: A. Armuzzi, A Orlando Bologna: F. Rizzello, M. Vecchi Thursday, May, 18 th Session 1 Patient s unmet needs in UC 13:00-13:20 Introduction Bologna: F. Rizzello Roma: A. Armuzzi Live from Rome 13:20-13:40 What patients surveys tell us A. Armuzzi Live from Bologna 13:40-14:00 Limits of conventional therapies M. Daperno Live from Rome 14: Limits of biological therapies M.L. Scribano Live from Rome and Bologna Discussion Session 2 Personalized therapy: how to profile the Patient Live from Bologna 14:30-14:50 Disease characteristics (Duration, extension, lesions previous RX) G.E. Tontini Live from Rome 14:50-15:10 The UC patient with other IMIDS (joint, skin, eye) M. Principi Live from Bologna 15:10-15:30 The UC patient with comorbidities (Diabetes, CHD, Previous K) S. Ardizzone Live from Rome and Bologna 15: Discussion 15:50 16:10 Coffee break

3 Thursday, May, 18 th Session 3 Therapeutic target in UC Live from Rome 16:10-16:30 Tight control: how to pursue in UC patients M. Fantini Live from Bologna 16:30-16:50 Adapting STRIDE consensus to real life management G. Fiorino Live from Rome 16:50-17:10 Hospital-based vs ehealth-based management F. Castiglione Live from Rome and Bologna 17:10-17:30 Discussion Session 4 Patient s tailored therapeutic strategies Live from Bologna 17:30-17:50 One size does not fit all M. Vecchi Live from Rome 17:50-18:10 Combination therapy: when and what to combine A. Orlando Live from Bologna 18:10-18:30 Changing the UC Course through Continuous Symptoms Control P. Gionchetti Live from Bologna 18:30-18:50 When the surgical approach S. Laureti Live from Rome and Bologna 18:50-19:20 Discussion

4 Chairmen Roma: A. Armuzzi, A Orlando Bologna: F. Rizzello, M. Vecchi Friday, May, 19 th Workshop Workshop Bologna: M. Daperno, F. Rizzello, E.V. Savarino Rome: F. Bossa, A. Testa, A. Viscido Monitoring disease activity in Clinical Practice: Biomarkers and Drug Monitoring Monitoring disease activity in Clinical Practice: Endoscopy and Histology Treatment Optimization in Clinical Practice Debriefing 12:10-12:40 Coffee break Live from Rome and Bologna :10 Workshop plenary discussion Live from Rome and Bologna 13.10:13:30 Closing remarks Bologna: F. Rizzello Rome: A. Armuzzi CME completion

5 Rationale Inflammatory Bowel Disease, namely Ulcerative Colitis and Crohn s disease, are disabling chronic diseases affecting young patients and majorly impacting on quality of life of patients suffering such conditions. IBD are treated by means of drugs or of surgical approach, according to co-existing disorders, or to severity and complexity of the disease itself. Both Crohn s disease and Ulcerative Colitis patients might be treated by means of aminosalycilates, steroids, immunosuppressors and/or biologic treatments provided that disease severity and clinical conditions required that given treatment. Patients with most severe/ complicated disease pattern, and patients un responsive to medical treatment, are candidates to respective surgery, which impact furthermore on quality of life and increasing disability. In the Ulcerative Colitis treatment, new therapeutic modalities became available in recent years, due to registration of new anti-tnf agents specifically for this indication (adalimumab or golimumab) and of drugs with different mechanism of action (vedolizumab). IG-IBD (Italian Group for Inflammatory Bowel Diseases) organised the educational event named Maximizing the outcome of UC therapy: the impact of a patient tailored approach specifically bearing in mind above mentioned therapeutic innovations, the increasing epidemiological burden of IBD overall and of ulcerative colitis more specifically, and the identification of most aggressive course of ulcerative colitis lastly. The educational meeting is expected to deeply insight novelties regarding Ulcerative Colitis epidemiology, prognostic factors, and treatment possibilities. Moreover, clinical cases will be presented and discussed in an interactive fashion, in order to make the programme and the activities as close as possible to everyday clinical decision-making, to ease interaction and networking among participants, and finally to promote a practical effect on the attitude of participating physicians in their clinical practice. The meeting will use a multimedia satellite-based platform, joining realtime 2 national areas concentrated into 2 spots (Rome and Bologna), so to offer an homogenous educational offer and to guarantee as much as possible topics close to clinical practice of intervening physicians.

6 Faculty live from Bologna Ardizzone Sandro Daperno Marco Fiorino Gionata Gionchetti Paolo Laureti Silvio Rizzello Fernando Savarino Edoardo Vincenzo Tontini Gian Eugenio Vecchi Maurizio Faculty live from Rome Armuzzi Alessandro Bossa Fabrizio Castiglione Fabiana Fantini Massimo Claudio Orlando Ambrogio Principi Mariabeatrice Scribano Maria Lia Testa Anna Viscido Angelo Responsabile Scientifico Rizzello Fernando Segreteria Scientifica Armuzzi Alessandro Daperno Marco Sede Bologna Novotel Bologna Fiera Via Michelino, Bologna Sede Roma NH Roma Villa Carpegna Via Pio IV, Roma Accreditamento ECM Il Corso è stato accreditato dal Provider PLS Educational Srl (evento Ed. 1) per la professione del Medico Chirurgo nelle discipline di Gastroenterologia, Medicina Interna e Chirurgia Generale. Il Corso prevede l assegnazione di 7 crediti formativi. Provider ECM e Segreteria Organizzativa PLS Educational Srl Via della Mattonaia, Firenze Tel: Fax: cristina.pizzo@promoleader.com Con il patrocinio di: AMICILazio onlus Associazione Malattie Infiammatorie Croniche Intestinali Malattia di Crohn Colite Ulcerosa